rosiglitazone has been researched along with Bladder Cancer in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dinney, CP; Ferguson, JE; Kamat, AM; Li, R; McConkey, DJ; Metcalfe, MJ; Mokkapati, S; Navai, N; Nogueras González, GM; Sahai, SK | 1 |
| Attalla, B; Bergholm, AM; Billger, M; Chadwick, KD; Chen, SJ; Czajkowski, M; Dorr, T; Foster, JR; Granaldi, K; Graziano, M; Haile, S; Janovitz, E; Mangipudy, R; Söderberg, M; Song, Y; Tirmenstein, M | 1 |
| Lei, C; Lv, S; Wang, H; Wang, W; Zhu, Y | 1 |
| Chang, C; Ding, XF; Li, LQ; Lin, SJ; Messing, E; Miyamoto, H; Wang, N; Yang, DR | 1 |
| Tseng, CH | 2 |
| Gau, CS; Hsiao, FY; Hsieh, PH; Huang, WF; Tsai, YW | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Badrick, E; Bell, S; Bowker, SL; Buchan, IE; Colhoun, HM; de Keyser, CE; Hartikainen, SA; Hofman, A; Johnson, JA; Keskimäki, I; Levin, D; MacDonald, TM; Marra, C; McKeigue, PM; Minhas-Sandhu, JK; Pukkala, E; Renehan, AG; Ruiter, R; Stricker, BH; Sund, R; Tuomilehto, J; Uitterlinden, AG; Wild, SH; Zafari, Z | 1 |
| Choe, EY; Han, E; Jang, SY; Kang, ES; Kim, G; Lee, YH; Nam, CM | 1 |
| Azoulay, L; Filion, KB; Platt, RW; Tuccori, M; Yin, H; Yu, OH | 1 |
| Desmond, R; Fischer, SM; Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE | 1 |
| Bowker, SL; Colmers, IN; Johnson, JA; Majumdar, SR | 1 |
| Bilker, WB; Glanz, K; Haynes, K; Lewis, JD; Mamtani, R; Strom, BL; Vaughn, DJ | 1 |
| Belgorosky, D; Eiján, AM; Langle, Y; Lodillinsky, C; Sandes, EO | 1 |
| Abdelrahim, M; Chintharlapalli, S; Kamat, AM; Kassouf, W; Nelkin, G; Safe, S | 1 |
3 review(s) available for rosiglitazone and Bladder Cancer
| Article | Year |
|---|---|
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
A review on thiazolidinediones and bladder cancer in human studies.
Topics: Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
Topics: Adult; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Humans; Incidence; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2012 |
13 other study(ies) available for rosiglitazone and Bladder Cancer
| Article | Year |
|---|---|
Effects of thiazolidinedione in patients with active bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cystectomy; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Neoplasm Staging; Pioglitazone; Retrospective Studies; Rosiglitazone; Survival Rate; Thiazolidinediones; Urinary Bladder Neoplasms | 2018 |
Evaluation of Uracil, Sodium Ascorbate, and Rosiglitazone as Promoters of Urinary Bladder Transitional Cell Carcinomas in Male Sprague-Dawley Rats.
Topics: Animals; Ascorbic Acid; Carcinogens; Carcinoma, Transitional Cell; Disease Models, Animal; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Uracil; Urinary Bladder; Urinary Bladder Neoplasms | 2018 |
PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway.
Topics: Animals; Apoptosis; Biomarkers; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Gene Expression Profiling; Humans; Immunohistochemistry; Male; Mice; Models, Biological; Phosphatidylinositol 3-Kinases; PPAR gamma; Prognosis; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Transcriptome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion.
Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; In Situ Hybridization, Fluorescence; PPAR gamma; Real-Time Polymerase Chain Reaction; RNA, Neoplasm; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2013 |
Rosiglitazone is not associated with an increased risk of bladder cancer.
Topics: Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Urinary Bladder Neoplasms | 2013 |
Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Pioglitazone; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Urinary Bladder Neoplasms | 2013 |
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
Topics: Aged; British Columbia; Diabetes Mellitus, Type 2; Female; Finland; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Rosiglitazone; Scotland; Thiazolidinediones; Urinary Bladder Neoplasms | 2015 |
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2016 |
Pioglitazone use and risk of bladder cancer: population based cohort study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; General Practice; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom; Urinary Bladder Neoplasms | 2016 |
Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
Topics: Animals; Butylhydroxybutylnitrosamine; Carcinogens; Cocarcinogenesis; Female; Immunohistochemistry; PPAR gamma; Rats; Rats, Inbred F344; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2008 |
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Topics: Aged; Cohort Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proportional Hazards Models; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom; Urinary Bladder Neoplasms | 2012 |
Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy.
Topics: Administration, Intravesical; Analysis of Variance; Animals; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Gene Expression Regulation; Humans; Immunohistochemistry; Mice; Mice, Inbred Strains; Mycobacterium bovis; Peroxisomes; PPAR gamma; Reference Values; Rosiglitazone; Sensitivity and Specificity; Thiazolidinediones; Tumor Burden; Urinary Bladder Neoplasms | 2012 |
Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Caveolin 1; Cell Cycle Proteins; Cell Growth Processes; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; PPAR gamma; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2006 |